litlas
ログインアカウント作成

Yuichi Sugiyama

1982–2026 年に発表

269
論文数
39,309
被引用数
115
h 指数
257
i10 指数

被引用数

Yuichi Sugiyama の年別被引用数1978 年: 被引用 1 件1982 年: 被引用 2 件1983 年: 被引用 4 件1984 年: 被引用 2 件1985 年: 被引用 7 件1986 年: 被引用 11 件1987 年: 被引用 2 件1988 年: 被引用 3 件1989 年: 被引用 3 件1990 年: 被引用 9 件1991 年: 被引用 13 件1992 年: 被引用 23 件1993 年: 被引用 31 件1994 年: 被引用 83 件1995 年: 被引用 67 件1996 年: 被引用 43 件1997 年: 被引用 81 件1998 年: 被引用 120 件1999 年: 被引用 183 件2000 年: 被引用 267 件2001 年: 被引用 298 件2002 年: 被引用 402 件2003 年: 被引用 471 件2004 年: 被引用 456 件2005 年: 被引用 512 件2006 年: 被引用 723 件2007 年: 被引用 525 件2008 年: 被引用 625 件2009 年: 被引用 562 件2010 年: 被引用 545 件2011 年: 被引用 480 件2012 年: 被引用 544 件2013 年: 被引用 468 件2014 年: 被引用 387 件2015 年: 被引用 289 件2016 年: 被引用 327 件2017 年: 被引用 282 件2018 年: 被引用 240 件2019 年: 被引用 875 件2020 年: 被引用 804 件2021 年: 被引用 617 件2022 年: 被引用 486 件2023 年: 被引用 354 件2024 年: 被引用 485 件2025 年: 被引用 240 件2026 年: 被引用 6 件1979〜1981 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,584 件、この内訳の 27.4%日本: 引用元論文 1,060 件、この内訳の 11.3%ドイツ: 引用元論文 668 件、この内訳の 7.1%イギリス: 引用元論文 634 件、この内訳の 6.7%中国: 引用元論文 592 件、この内訳の 6.3%オランダ: 引用元論文 371 件、この内訳の 3.9%スイス: 引用元論文 290 件、この内訳の 3.1%フランス: 引用元論文 275 件、この内訳の 2.9%カナダ: 引用元論文 250 件、この内訳の 2.7%スウェーデン: 引用元論文 244 件、この内訳の 2.6%イタリア: 引用元論文 196 件、この内訳の 2.1%韓国: 引用元論文 173 件、この内訳の 1.8%
0%27.4%その他 22.1%

機関

分野

  • Medicine59.4%
  • Biochemistry, Genetics and Molecular Biology12%
  • Pharmacology, Toxicology and Pharmaceutics11.6%
  • Materials Science4.2%
  • Computer Science3.3%
  • Engineering2.3%
  • その他7.2%

トピック

  • Drug Transport and Resistance Mechanisms15.1%
  • Pharmacogenetics and Drug Metabolism6.6%
  • Pharmacological Effects and Toxicity Studies5.9%
  • Computational Drug Discovery Methods2.8%
  • Nanoparticle-Based Drug Delivery1.9%
  • Drug-Induced Hepatotoxicity and Protection1.8%
  • その他65.9%

共著者

全論文

検索で開く
  1. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME

    著者: Patrício Godoy, Nicola J. Hewitt, Ute Albrecht, Melvin E. Andersen, Nariman Ansari, Sudin Bhattacharya, Johannes G. Bode, Jennifer Bolleyn, Christoph Borner, J Böttger, Albert Braeuning, Robert A. Budinsky, Britta Burkhardt, Neil R. Cameron, Giovanni Camussi, Chong-Su Cho, Yun-Jaie Choi, J. Craig Rowlands, Uta Dahmen, Georg Damm, Olaf Dirsch, M. Teresa Donato, Jian Dong, Steven Dooley, Dirk Drasdo, Rowena Eakins, Karine Sá Ferreira, Valentina Fonsato, Joanna Fraczek, Rolf Gebhardt, Andrew Gibson, Matthias Glanemann, Christopher E. Goldring, Marı́a José Gómez-Lechón, Geny M. M. Groothuis, Lena Gustavsson, Christelle Guyot, David Hallifax, Seddik Hammad, Adam S. Hayward, Dieter Häussinger, Claus Hellerbrand, Philip Hewitt, Stefan Hoehme, Hermann−Georg Holzhütter, J. Brian Houston, Jens Hrach, Kiyomi Ito, Hartmut Jaeschke, Verena Keitel, Jens Kelm, B. Kevin Park, Claus Kordes, Gerd A. Kullak‐Ublick, Edward L. LeCluyse, Peng Lü, Jennifer L. Luebke-Wheeler, Anna Lutz, Daniel J. Maltman, Madlen Matz‐Soja, Patrick D. McMullen, Irmgard Merfort, Simon Messner, Christoph Meyer, Jessica Mwinyi, Dean J. Naisbitt, Andreas K. Nüssler, Peter Olinga, Francesco Pampaloni, Jingbo Pi, Linda Pluta, Stefan Przyborski, Anup Ramachandran, Vera Rogiers, Cliff Rowe, Celine Schelcher, Kathrin Schmich, Michael Schwarz, Bijay Singh, Ernst H. K. Stelzer, Bruno Stieger, Regina Stöber, Yuichi Sugiyama, Ciro Tetta, Wolfgang E. Thasler, Tamara Vanhaecke, Mathieu Vinken, Thomas S. Weiß, A Widera, Courtney G. Woods, Jinghai J. Xu, Kathy Yarborough, Jan G. Hengstler - Archives of Toxicology 2013 被引用: 1,275

  2. Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

    著者: Xiaoyan Chu, Mingxiang Liao, Hong Shen, Kenta Yoshida, Arik A. Zur, Vikram Arya, Aleksandra Galetin, Kathleen M. Giacomini, Imad Hanna, Hiroyuki Kusuhara, Yurong Lai, David Rodrigues, Yuichi Sugiyama, Maciej J. Zamek‐Gliszczynski, Lei Zhang - Clinical Pharmacology & Therapeutics 2018 被引用: 198

  3. Physiologically‐Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug–Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations

    著者: Kunal S. Taskar, Venkatesh Pilla Reddy, Howard Burt, Maria M. Posada, Manthena V. S. Varma, Ming Zheng, Mohammed Ullah, Arian Emami Riedmaier, Kenichi Umehara, Jan Snoeys, Masanori Nakakariya, Xiaoyan Chu, Maud Bénéton, Yuan Chen, Felix Huth, Rangaraj Narayanan, Dwaipayan Mukherjee, Vaishali Dixit, Yuichi Sugiyama, Sibylle Neuhoff - Clinical Pharmacology & Therapeutics 2019 被引用: 141

  4. Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin

    著者: Desheng Wang, Johan W. Jonker, Yukio Kato, Hiroyuki Kusuhara, Alfred H. Schinkel, Yuichi Sugiyama - Journal of Pharmacology and Experimental Therapeutics 2002 被引用: 442

  5. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions

    著者: Yoshihisa Shitara, Yuichi Sugiyama - Pharmacology & Therapeutics 2006 被引用: 574

  6. Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches

    著者: Yingying Guo, Xiaoyan Chu, Neil Parrott, Kim L. R. Brouwer, Vicky Hsu, Swati Nagar, Pär Matsson, Pradeep Sharma, Jan Snoeys, Yuichi Sugiyama, Daniel Tatosian, Jashvant D. Unadkat, Shiew‐Mei Huang, Aleksandra Galetin - Clinical Pharmacology & Therapeutics 2018 被引用: 116

  7. Identification of Appropriate Endogenous Biomarker for Risk Assessment of Multidrug and Toxin Extrusion Protein‐Mediated Drug‐Drug Interactions in Healthy Volunteers

    著者: Takeshi Miyake, Emi Kimoto, Lina Luo, Sumathy Mathialagan, Lauren Horlbogen, Ragu Ramanathan, Linda S. Wood, Jillian G. Johnson, Vu Le, Manoli Vourvahis, A. David Rodrigues, Chieko Muto, Kenichi Furihata, Yuichi Sugiyama, Hiroyuki Kusuhara - Clinical Pharmacology & Therapeutics 2020 被引用: 46

  8. Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

    著者: Sook Wah Yee, Deanna J. Brackman, E Ennis, Yuichi Sugiyama, Landry K. Kamdem, Rebecca Blanchard, Aleksandra Galetin, Lei Zhang, Kathleen M. Giacomini - Clinical Pharmacology & Therapeutics 2018 被引用: 137

  9. Efflux of a suppressive neurotransmitter, GABA, across the blood–brain barrier

    著者: Atsuyuki Kakee, Hitomi Takanaga, Tetsuya Terasaki, Mikihiko Naito, Takashi Tsuruo, Yuichi Sugiyama - Journal of Neurochemistry 2001 被引用: 114

  10. PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3

    著者: Takashi Yoshikado, Kota Toshimoto, Kazuya Maeda, Hiroyuki Kusuhara, Emi Kimoto, A. David Rodrigues, Kōji Chiba, Yuichi Sugiyama - CPT Pharmacometrics & Systems Pharmacology 2018 被引用: 75

  11. N-Methylnicotinamide Is an Endogenous Probe for Evaluation of Drug–Drug Interactions Involving Multidrug and Toxin Extrusions (MATE1 and MATE2-K)

    著者: S Ito, Hiroyuki Kusuhara, Yoshito Kumagai, Yoshinori Moriyama, Katsuhisa Inoue, Tsunenori Kondo, Hideki Nakayama, Shigeru Horita, Kiyoshi Tanabe, Hiroaki Yuasa, Yuichi Sugiyama - Clinical Pharmacology & Therapeutics 2012 被引用: 105

  12. Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs

    著者: Daiki Mori, Emi Kimoto, Brian Rago, Yusuke Kondo, Amanda King‐Ahmad, Ragu Ramanathan, Linda S. Wood, Jillian G. Johnson, Vu Le, Manoli Vourvahis, A. David Rodrigues, Chieko Muto, Kenichi Furihata, Yuichi Sugiyama, Hiroyuki Kusuhara - Clinical Pharmacology & Therapeutics 2019 被引用: 102

  13. Transporters in Drug Development: International Transporter Consortium Update on Emerging Transporters of Clinical Importance

    著者: Maciej J. Zamek‐Gliszczynski, Vishal Sangha, Hong Shen, Bo Feng, Matthias Wittwer, Manthena V. S. Varma, Xiaomin Liang, Yuichi Sugiyama, Lei Zhang, Reina Bendayan - Clinical Pharmacology & Therapeutics 2022 被引用: 60

  14. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.

    著者: Nobuhiro Nishiyama, Souichiro Okazaki, Horacio Cabral, Masaki Miyamoto, Yukio Kato, Yuichi Sugiyama, Kazuto Nishio, Yasuhiro Matsumura, Kazunori Kataoka - 2003 被引用: 602

  15. Transporters as a determinant of drug clearance and tissue distribution

    著者: Yoshihisa Shitara, Toshiharu Horie, Yuichi Sugiyama - European Journal of Pharmaceutical Sciences 2006 被引用: 491

  16. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans

    著者: Masaru Hirano, Kazuya Maeda, Yoshihisa Shitara, Yuichi Sugiyama - Journal of Pharmacology and Experimental Therapeutics 2004 被引用: 442

  17. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption

    著者: Yoshihisa Shitara, Kazuya Maeda, Kazuaki Ikejiri, Kenta Yoshida, Toshiharu Horie, Yuichi Sugiyama - Biopharmaceutics & Drug Disposition 2012 被引用: 414

  18. Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development

    著者: Masato Chiba, Yasuyuki Ishii, Yuichi Sugiyama - The AAPS Journal 2009 被引用: 227

  19. Competitive Inhibition of the Luminal Efflux by Multidrug and Toxin Extrusions, but Not Basolateral Uptake by Organic Cation Transporter 2, Is the Likely Mechanism Underlying the Pharmacokinetic Drug-Drug Interactions Caused by Cimetidine in the Kidney

    著者: Sumito Ito, Hiroyuki Kusuhara, Miyu Yokochi, Junko Toyoshima, Katsuhisa Inoue, Hiroaki Yuasa, Yuichi Sugiyama - Journal of Pharmacology and Experimental Therapeutics 2011 被引用: 210

  20. Phase 0/microdosing approaches: time for mainstream application in drug development?

    著者: Tal Burt, Graeme Young, Wooin Lee, Hiroyuki Kusuhara, Oliver Langer, Malcolm Rowland, Yuichi Sugiyama - Nature Reviews Drug Discovery 2020 被引用: 101

  21. Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions

    著者: Tatsuki Mochizuki, Maciej J. Zamek‐Gliszczynski, Kenta Yoshida, Jialin Mao, Kunal S. Taskar, Hideki Hirabayashi, Xiaoyan Chu, Yurong Lai, Tadayuki Takashima, Kevin Rockich, Yoshiyuki Yamaura, Kaku Fujiwara, Tadahaya Mizuno, Kazuya Maeda, Kenichi Furihata, Yuichi Sugiyama, Hiroyuki Kusuhara - Clinical Pharmacology & Therapeutics 2022 被引用: 37

  22. Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver

    著者: Xiaoyan Chu, Ken Korzekwa, Robert Elsby, Katherine S. Fenner, Aleksandra Galetin, Yurong Lai, Pär Matsson, Aaron M. Moss, Swati Nagar, Gus R. Rosania, Jingwen Bai, Joseph W. Polli, Yuichi Sugiyama, Kim L. R. Brouwer - Clinical Pharmacology & Therapeutics 2013 被引用: 232

  23. Endogenous Probes for Drug Transporters: Balancing Vision With Reality

    著者: AD Rodrigues, KS Taskar, Hiroyuki Kusuhara, Yuichi Sugiyama - Clinical Pharmacology & Therapeutics 2017 被引用: 99

  24. Investigation of Endogenous Compounds Applicable to Drug–Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans

    著者: Yuri Tsuruya, Koji Kato, Yamato Sano, Yuichiro Imamura, Kazuya Maeda, Yuji Kumagai, Yuichi Sugiyama, Hiroyuki Kusuhara - Drug Metabolism and Disposition 2016 被引用: 75